ArticleParkinson's disease2026
Dynamic Changes in Midbrain-Striatal Association and Their Relationship With Levodopa-Induced Dyskinesia in Parkinson's Disease.
Article in Parkinson's disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Dynamic Changes in Midbrain-Striatal Association and Their Relationship With Levodopa-Induced Dyskinesia in Parkinson's Disease.Parkinson's disease · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The neurobiological pathology of levodopa-induced dyskinesia (LID) remains unclear despite its prevalence. Emerging evidence suggests a critical interplay between dopaminergic and serotonergic systems in the development of LID. Objective: This study aimed to investigate longitudinal changes in striatal and midbrain SBRs and their association with LID development, with exploratory evaluation of midbrain-striatal monoaminergic coupling. Methods: A total of 169 drug-naïve PD patients from the PPMI database were followed over four years. I-123 FP-CIT SPECT imaging was used to measure specific binding ratios (SBRs) in the caudate, putamen, and midbrain. Patients were categorized into LID and non-LID groups at follow-up. Interregional correlation analysis assessed the correlation between midbrain and striatal subregions. The impact of levodopa-equivalent daily dose (LEDD) on correlation was also evaluated. Results: The LID group exhibited significantly lower striatal SBRs at baseline and follow-up compared to the non-LID group. Midbrain SBRs declined more steeply in the LID group over time. In multivariable regression models adjusting for baseline clinical differences, the interaction between midbrain SBR and LID status for the 4-year putamen SBR showed a trend-level association ( Conclusion: Our findings suggest a dynamic pattern in which early relative preservation of nonstriatal monoaminergic signals, reflected by midbrain SBR changes, may accompany dopaminergic loss in patients who develop LID. Midbrain SBR should be interpreted as a proxy of monoaminergic integrity rather than a direct serotonergic biomarker. LID appears to mark a phenotype of accelerated nigrostriatal degeneration characterized by lower baseline and faster longitudinal decline of putaminal SBR. Midbrain-striatal coupling patterns may reflect secondary monoaminergic network changes associated with disease progression rather than a causal serotonergic mechanism.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.